Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy (Adv. Mater. 39/2025)

Cancer Immunotherapy In article number 2501565, Xu Chen, Yihang Pan, Tianxin Lin, and co-workers have established a platform utilizing a CRISPR system-based bacterial outer membrane vesicle (OMV) for the efficient and cost-effective targeted delivery of plasmids. The intravesical administration of these engineered OMVs, which encoding CXCL-9 and IL-12, have been shown to effectively facilitating T-cell infiltration and activation. This process enhances the anti-tumor efficacy of OMV-mediated therapies and increases sensitivity to anti-PD-1/PD-L1 treatments. Consequently, this approach presents a novel strategy to address resistance to immunotherapy in the context of bladder cancer.

Authors

Institutions

Publication Details

Journal
Advanced Materials
Published
2025-10-01
DOI
https://doi.org/10.1002/adma.70627
Citations
1
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
1.23
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy (Adv. Mater. 39/2025)

Xiao Zhao, Siting Chen, Shengmeng Peng, Junlin Lu et al.
1 citations
Advanced Materials
Cancer Research and Treatments
1.23
article

Engineering CRISPR System‐Based Bacterial Outer Membrane Vesicle Potentiates T Cell Immunity for Enhanced Cancer Immunotherapy (Adv. Mater. 39/2025)

Xiao Zhao, Siting Chen, Shengmeng Peng, Junlin Lu, Bailin Pan, Xuwei Hong, Hongjin Wang, Xinrou Lin, Changhao Chen, Jianmei Zhong, Hengji Zhan, Leli Zeng, Wenlong Zhong, Ye Li, Qiang Zhang, Xu Chen, Zehua Chen, Yihang Pan, Jiajian Lai, Tianxin Lin, Shaoxu Wu, Sen Liu, Kaiwen Jie
article en
1 citations

Abstract

Cancer Immunotherapy In article number 2501565, Xu Chen, Yihang Pan, Tianxin Lin, and co-workers have established a platform utilizing a CRISPR system-based bacterial outer membrane vesicle (OMV) for the efficient and cost-effective targeted delivery of plasmids. The intravesical administration of these engineered OMVs, which encoding CXCL-9 and IL-12, have been shown to effectively facilitating T-cell infiltration and activation. This process enhances the anti-tumor efficacy of OMV-mediated therapies and increases sensitivity to anti-PD-1/PD-L1 treatments. Consequently, this approach presents a novel strategy to address resistance to immunotherapy in the context of bladder cancer.

Advanced MaterialsVol. 37(39)
Sun Yat-sen University (CN), The Seventh Affiliated Hospital of Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN), Shantou Central Hospital (CN), Third Affiliated Hospital of Sun Yat-sen University (CN)
Openalex Percentile: Top 18%
Cancer Research and Treatments
1.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.